Tesamorelin

The peptide matches native GHRH(1–44) with a single amino-acid substitution that increases its stability in the blood. It contains only natural L-amino acids and no non-natural modifications beyond that substitution. Tesamorelin is made by solid-phase peptide synthesis and purified by HPLC to ≥95 % purity. Mass spectrometry confirms its correct sequence and purity.

Tesamorelin binds to GHRH receptors on pituitary somatotrophs, triggering cyclic AMP signaling and release of endogenous GH. The resulting GH pulses stimulate the liver and other tissues to produce insulin-like growth factor-1 (IGF-1). This mimics the body’s natural GH regulation. Increased GH/IGF-1 activity promotes fat metabolism in specific compartments.

The peptide is used to reduce excess visceral (abdominal) fat in HIV-infected adults with lipodystrophy. In clinical trials, once-daily tesamorelin decreased visceral adipose tissue and improved waist circumference. Patients also saw stable insulin sensitivity and no major changes in glucose control. Its targeted action addresses fat distribution without direct drug therapy for HIV.

Common adverse events include mild injection-site reactions, joint pain, and muscle aches. Elevated IGF-1 can occur but remains within safe ranges. Rarely, tesamorelin may worsen glucose tolerance; regular blood-sugar monitoring is advised. It is contraindicated in active malignancy and in women who are pregnant or breastfeeding.

Tesamorelin is produced by Fmoc solid-phase peptide synthesis, assembling 44 amino acids on resin. After cleavage, it is purified by preparative HPLC to clinical-grade purity. Analytical HPLC and mass spectrometry verify sequence integrity and purity. Manufacturing follows pharmaceutical GMP standards.

Tesamorelin (brand name Egrifta SV) is FDA-approved for HIV-associated lipodystrophy in adults. It is prescription-only and dispensed through specialty pharmacies. Its use outside that indication is off-label and not routinely supported by regulatory bodies.

The approved dose is 2 mg subcutaneous once daily, injected into the abdomen. No dose escalation is required. Treatment duration is up to 26 weeks based on clinical response and safety monitoring.

Do administer daily at around the same time to maintain steady GH pulses.Do monitor IGF-1 levels and fasting glucose regularly.Don’t use in patients with active cancer or suspected pituitary adenoma.Don’t use during pregnancy or lactation.

Q: How soon does fat loss appear?A: Significant reductions in abdominal fat are seen after 12 weeks of daily dosing.Q: Does it improve HIV outcomes?A: It does not affect HIV viral load or immune status.Q: Can non-HIV patients use it?A: No; its approval and safety data are limited to HIV-associated lipodystrophy.